New tuberculosis drugs on the horizon

Current Opinion in Microbiology

Volumn 14, Issue 5, 2011, Pages 570-576

  Cole, Stewart T ^a   Riccardi, Giovanna ^b  

^a EPFL   (Switzerland)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AZD 5847; BEDAQUILINE; BENZOTHIAZINONE; BTZ 043; CYTOCHROME P450 3A4; DELAMANID; DINITROBENZAMIDE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LINEZOLID; MOXIFLOXACIN; MYCOLIC ACID; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; PNU 100480; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAMYCIN; RIFAPENTINE; RNA POLYMERASE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; VI 9376;

BACTERIAL CELL WALL; BACTERICIDAL ACTIVITY; CELL ACTIVITY; CELL RESPIRATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG RESISTANT TUBERCULOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EUKARYOTIC CELL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FATTY ACID SYNTHESIS; GENE MUTATION; HIGH THROUGHPUT SCREENING; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM SMEGMATIS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; MYCOBACTERIUM TUBERCULOSIS; RESEARCH; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

EID: 80053902179     PISSN: 13695274     EISSN: 18790364     Source Type: Journal    
DOI: 10.1016/j.mib.2011.07.022     Document Type: Review

References (47)

1. Glaziou P., Floyd K., Raviglione M. Global burden and epidemiology of tuberculosis. Clin Chest Med 2009, 30:621-636.
2. Chao M.C., Rubin E.J. Letting sleeping dos lie: does dormancy play a role in tuberculosis?. Annu Rev Microbiol 2010, 64:293-311.
3. Harrington M. From HIV to tuberculosis and back again: a tale of activism in 2 pandemics. Clin Infect Dis 2010, 50(Suppl. 3):S260-S266.
4. Cegielski J.P. Extensively drug-resistant tuberculosis: there must be some kind of way out of here. Clin Infect Dis 2010, 50(Suppl. 3):S195-S200.
5. Carvalho A.C., Migliori G.B., Cirillo D.M. Tuberculosis in Europe: a problem of drug resistance or much more?. Expert Rev Respir Med 2010, 4:189-200.
6. Fu L.M. The potential of human neutrophil peptides in tuberculosis therapy. Int J Tuberc Lung Dis 2003, 7:1027-1032.
7. Velayati A.A., Masjedi M.R., Farnia P., Tabarsi P., Ghanavi J., Ziazarifi A.H., Hoffner S.E. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran. Chest 2009, 136:420-425.
8. Harries A.D., Zachariah R., Corbett E.L., Lawn S.D., Santos-Filho E.T., Chimzizi R., Harrington M., Maher D., Williams B.G., De Cock K.M. The HIV-associated tuberculosis epidemic - when will we act?. Lancet 2010, 375:1906-1919.
9. Payne D.J., Gwynn M.N., Holmes D.J., Pompliano D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007, 6:29-40.
10. Fischbach M.A., Walsh C.T. Antibiotics for emerging pathogens. Science 2009, 25:1089-1093.
11. Riccardi G., Pasca M.R., Buroni S. Mycobacterium tuberculosis: drug resistance and future perspectives. Future Microbiol 2009, 4:597-614.
12. Ma Z., Lienhardt C., McIlleron H., Nunn A.J., Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010, 375:2100-2109.
13. Lalloo U.G., Ambaram A. New antituberculous drugs in development. Curr HIV/AIDS Rep 2010, 7:143-151.
14. Leibert E., Rom W.N. New drugs and regimens for treatment of TB. Expert Rev Anti Infect Ther 2010, 8:801-813.
15. Shi R., Sugawara I. Development of new anti-tuberculosis drug candidates. Tohoku J Exp Med 2010, 221:97-106.
16. Burman W.J. Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century. Clin Infect Dis 2010, 50(Suppl. 3):S165-S172.
17. Barry C.E., Blanchard J.S. The chemical biology of new drugs in the development for tuberculosis. Curr Opin Chem Biol 2010, 14:456-466.
18. García-Tapia A., Rodríguez J.C., Ruiz M., Royo G. Action of fluoroquinolones and Linezolid on logarithmic- and stationary-phase culture of Mycobacterium tuberculosis. Chemotherapy 2004, 50:211-213.
19. Matteelli A., Carvalho A.C., Dooley K.E., Kritski A. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010, 5:849-858.
20. Andries K., Verhasselt P., Guillemont J., Göhlmann H.W., Neefs J.M., Winkler H., Van Gestel J., Timmerman P., Zhu M., Lee E., et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005, 307:223-227.
21. Haagsma A.C., Abdillahi-Ibrahim R., Wagner M.J., Krab K., Vergauwen K., Guillemont J., Andries K., Lill H., Koul A., Bald D. Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotic homologue. Antimicrob Agents Chemother 2009, 53:1290-1292.
22. Huitric E., Verhasselt P., Koul A., Andries K., Hoffner S., Andersson D.I. Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob Agents Chemother 2010, 54:1022-1028.
23. Rao S.P., Alonso S., Rand L., Dick T., Pethe K. The protonmotive force is required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2008, 105:11945-11950.
24. Bald D., Koul A. Respiratory ATP synthesis: the new generation of mycobacterial drug targets?. FEMS Microbiol Lett 2010, 308:1-7.
25. Singh R., Manjunatha U., Boshoff H.I., Ha Y.H., Niyomrattanakit P., Ledwidge R., Dowd C.S., Lee I.Y., Kim P., Zhang L., et al. PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science 2008, 322:392-395.
26. Manjunatha U.H., Lahiri R., Randhawa B., Dowd C.S., Krahenbuhl J.L., Barry C.E. Mycobacterium leprae is naturally resistant to PA-824. Antimicrob Agents Chemother 2006, 50:350-354.
27. Manjunatha U., Boshoff H.I., Barry C.E. The mechanism of action of PA-824: Novel insights from transcriptional profiling. Commun Integr Biol 2009, 2:215-218.
28. Matsumoto M., Hashizume H., Tomishige T., Kawasaki M., Tsubouchi H., Sasaki H., Shimokawa Y., Komatsu M. OPC-67683 a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med 2006, 3:e466.
29. Ahmad Z., Peloquin C.A., Singh R.P., Derendorf H., Tyagi S., Ginsberg A., Grosset J.H., Nuermberger E.L. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother 2011, 55:239-245.
30. Boshoff H.I., Myers T.G., Copp B.R., McNeil M.R., Wilson M.A., Barry C.E. The transcriptional responses of Mycobacterium tuberculosis to inhibitors of metabolism: novel insights into drug mechanisms of action. J Biol Chem 2004, 279:40174-40184.
31. Reddy V.M., Einck L., Andries K., Nacy C.A. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207. Antimicrob Agents Chemother 2010, 54:2840-2846.
32. Rosenthal I.M., Zhang M., Williams K.N., Peloquin C.A., Tyagi S., Vernon A.A., Bishai W.R., Chaisson R.E., Grosset J.H., Nuermberger E.L. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007, 4:e344.
33. Bobkova E.V., Yan Y.P., Jordan D.B., Kurilla M.G., Pompliano D.L. Catalytic properties of mutant 23 S ribosomes resistant to oxazolidinones. J Biol Chem 2003, 278:9802-9807.
34. Bozdogan B., Appelbaum P.C. Oxazolidinones: activity, mode of action, and mechanism of resistance. Int J Antimicrob Agents 2004, 23:113-119.
35. De Bus L., Depuydt P., Libbrecht L., Vandekerckhove L., Nollet J., Benoit D., Vogelaers D., Van Vlierberghe H. Severe drug-induced liver injury associated with prolonged use of linezolid. J Med Toxicol 2010, 6:322-326.
36. Fortun J., Martin-Davila P., Navas E., Perez-Elias M.J., Cobo J., Tato M., De la Pedrosa E.G., Gomez-Mampaso E., Moreno S. Linezolid for the treatment of multidrug-resistant tuberculosis. J Antimicrob Chemother 2005, 56:180-185.
37. Wallis R.S., Jakubiec W.M., Kumar V., Silvia A.M., Paige D., Dimitrova D., Li X., Ladutko L., Campbell S., Friedland G., et al. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis 2010, 202:745-751.
38. Wallis R.S., Jakubiec W., Kumar V., Bedarida G., Silvia A., Paige D., Zhu T., Mitton-Fry M., Ladutko L., Campbell S., et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother 2011, 55:567-574.
39. Williams K.N., Brickner S.J., Stover C.K., Zhu T., Ogden A., Tasneen R., Tyagi S., Grosset J.H., Nuermberger E.L. Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med 2009, 180:371-376.
40. Makarov V., Manina G., Mikusova K., Möllmann U., Ryabova O., Saint-Joanis B., Dhar N., Pasca M.R., Buroni S., Lucarelli A.P., et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. Science 2009, 324:801-804.
41. Christophe T., Jackson M., Jeon H.K., Fenistein D., Contreras-Dominguez M., Kim J., Genovesio A., Carralot J.P., Ewann F., Kim E.H., et al. High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog 2009, 5:e1000645.
42. Magnet S., Hartkoorn R.C., Székely R., Pató J., Triccas J.A., Schneider P., Szántai-Kis C., Orfi L., Chambon M., Banfi D., et al. Leads for antitubercular compounds from kinase inhibitor library screens. Tuberculosis (Edinb) 2010, 90:354-360.
43. Mikusová K., Huang H., Yagi T., Holsters M., Vereecke D., D'Haeze W., Scherman M.S., Brennan P.J., McNeil M.R., Crick D.C. Decaprenylphosphoryl arabinofuranose, the donor of the d-arabinofuranosyl residues of mycobacterial arabinan, is formed via a two-step epimerization of decaprenylphosphoryl ribose. J Bacteriol 2005, 187:8020-8025.
44. Wolucka B.A. Biosynthesis of d-arabinose in mycobacteria - a novel bacterial pathway with implications for antimycobacterial therapy. FEBS J 2008, 275:2691-2711.
45. Trefzer C., Rengifo-Gonzalez M., Hinner M.J., Schneider P., Makarov V., Cole S.T., Johnsson K. Benzothiazinones: prodrugs that covalently modify the decaprenylphosphoryl-beta-d-ribose 2'-epimerase DprE1 of Mycobacterium tuberculosis. J Am Chem Soc 2010, 132:13663-13665.
46. Pasca M.R., Degiacomi G., Ribeiro A.L., Zara F., De Mori P., Heym B., Mirrione M., Brerra R., Pagani L., Pucillo L., et al. Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones. Antimicrob Agents Chemother 2010, 54:1616-1618.
47. Manina G., Pasca M.R., Buroni S., De Rossi E., Reccardi G. Decaprenylphosphoryl-β-d-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target. Curr Med Chem 2010, 17:3099-3108.